As of 01 December 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] and (2) Lenvatinib [4 mg/10 mg capsule] for adults diagnosed with advanced continue reading : HTA Council Preliminary Recommendation on (1) Atezolizumab + Bevacizumab and (2) Lenvatinib for Adults Diagnosed with Advanced or Unresectable Hepatocellular Cancer (HCC)